Elena Matsa, PhD - Director, of Discovery Technology, NcardiaTravis Hardcastle - Associate Product Manager of Cell Line Products, Horizon Discovery
Induced pluripotent stem cells (iPSCs) have revolutionized life sciences research efforts, especially when trying to understand the underlying causes of debilitating human diseases. Combining iPSC technology with cutting-edge genome editing methodologies provides a unique opportunity for investigators to create an array of disease models that will become integral for developing new therapeutic approaches. We have already seen a steady rise in the use of human iPSCs for disease modeling, which, initiating in academia, have now infiltrated the biopharmaceutical industry. In this GEN webinar, we will provide a field overview of how iPSCs, coupled with genome editing, hold the potential to expand our understanding of human diseases further and facilitate the development of new therapies.